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 24 
Abstract 25 
Objective: Some lipid-lowering agents, for example, nicotinic acid and fibrates, decrease an individual’s 26 
ability to metabolise fat during exercise. However, it is unclear whether statins affect fat metabolism during 27 
exercise in patients. This study investigated whether fatty acid oxidation is impaired in a dyslipidemic 28 
population, while walking at a moderate intensity. 29 
Methods: Patients (n=16), walked for 45 minutes on a treadmill at 50% of their estimated V̇O2max, in 30 
the absence and presence of their prescribed statin. Fat metabolism was investigated by examining 31 
respiratory data, and circulating plasma glycerol and free fatty acids. 32 
Results: Analysis of respiratory data indicated a progressive increase in fat oxidation over time, along 33 
with a decrease in carbohydrate oxidation, for all patients during exercise, in both the absence and 34 
presence of a statin (P≤0.05). The increase in the percent of energy derived from fat was further 35 
supported by the observation of a significantly progressive increase in circulating glycerol and free fatty 36 
acids during the exercise period. However no significant difference in the extent of change was observed 37 
when comparing the respiratory and biochemical response to physical activity in the absence and 38 
presence of the prescribed statin. 39 
Conclusions: There is no evidence of a negative impact of statins on the ability to metabolise fat as a 40 
fuel for moderate-intensity aerobic exercise. Given the importance of physical activity, this result 41 
encourages patients to participate in regular exercise without concern of premature fatigue.  42 
 43 
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Introduction 47 
Lipid-lowering drugs are amongst the most commonly subsidized prescribed drugs world-wide, 48 
including Europe and the United States (USA). In 2016, atorvastatin and simvastatin were ranked in 49 
positions 1 and 7 in the USA [1]. In the same year, in Australia, atorvastatin and rosuvastatin were in 50 
positions 1 and 3, with the number of Australians per thousand taking the drug daily being 53 for 51 
atorvastatin and 34 for rosuvastatin [2].  52 
Physiologically, these drugs inhibit liver enzyme HMG-CoA reductase, blocking cholesterol 53 
synthesis. They are recognized as effective in the secondary prevention of cardiovascular disease and 54 
all-cause mortality [3]. However, it is now well established that a healthy diet and regular physical 55 
activity are valuable contributors to maintaining healthy blood lipids, with exercise improving 56 
cardiovascular fitness; reducing all-cause mortality and the risk of coronary heart and cardiovascular 57 
disease, stroke, type 2 diabetes mellitus (T2DM), and obesity. A recent meta-analysis highlighted that 58 
physical activity alone is potentially as effective as many drug interventions on mortality outcomes in 59 
coronary heart disease, stroke, heart failure, and prediabetes [4]. Despite this, there exists a bias against 60 
exercise intervention with a subsequent progression towards lowering the threshold for pharmaceutical 61 
treatment, and an increased likelihood that individuals embarking on an exercise regime are already 62 
taking a cholesterol-lowering agent as a secondary or even primary prevention against cardiovascular 63 
risk. To maximize the benefit of pharmaceutical intervention and exercise, it is important therefore, to 64 
understand the effect of these drugs on the body’s response to exercise. 65 
Lipid stores, critical for fueling prolonged exercise, exist as triglycerides in adipose tissue and 66 
muscle, and also as circulating triglycerides. Hormone-sensitive lipase (HSL), an intracellular enzyme in 67 
adipose tissue, and lipoprotein lipase (LPL), an enzyme which hydrolyzes the triglyceride core of 68 
circulating chylomicrons, both liberate free fatty acids (FFA) for use by exercising muscle. Any drugs 69 
acting at these sites, could potentially alter FFA availability, resulting in increasing dependence on 70 
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muscle glycogen stores and earlier fatigue [5]. Studies in healthy volunteers undertaking exercise have 71 
found that the lipid-lowering drugs, acipimox, and fibrates such as bezafibrate and gemfibrozil, have a 72 
negative impact on fat oxidation [5,6]. This increases demand for carbohydrate (CHO), and is thought to 73 
contribute to a reduction in exercise tolerance. However, no negative impact of simvastatin, fluvastatin 74 
or atorvastatin has been observed in healthy exercising participants [5,6,7].  75 
In contrast, the impact of statins on fat metabolism in patient cohorts is less clear. The available 76 
research in patients undergoing exercise has produced conflicting results, with studies confounded by 77 
the co-administration of a kaleidoscope of other cholesterol-lowering agents, or with β-blockers, which 78 
inhibit the release of FFA from adipose tissue and complicate the interpretation of the data [8,9]. One 79 
study in patients has reported reduced fat oxidation with atorvastatin, during lower-intensity exercise 80 
[10]. Patients have also self-reported increased fatigue with exertion after taking simvastatin for a period 81 
of 6 months [11]. In contrast, other studies have reported no negative impact of statins on fat metabolism 82 
[12,13]. 83 
Given the importance of exercise in these patients, and the limited and conflicting data on the 84 
interaction between cholesterol-lowering agents and physical activity, the current study investigated in a 85 
dyslipidemic population, whether statins impair fatty acid oxidation during exercise of moderate-86 
intensity. This study is unique as it appears to be the first longitudinal investigation of fat metabolism in 87 
both the absence and presence of a statin during exercise, within the same group of patients.  88 
 89 
 90 
 91 
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Method 93 
 94 
Participants 95 
The study engaged 16 Caucasian adults taking a statin for hypercholesterolemia. The study was 96 
approved by the Human Research Ethics Committees from The University of New South Wales (UNSW) 97 
(HREC05310) and the Sydney Adventist Hospital (HREC12/06) and all procedures were in accordance 98 
with institutional guidelines. Participants were recruited by newspaper advertisements, and required 99 
written permission from their medical practitioner to participate. Individuals also provided written 100 
informed consent, and were aware of their right to withdraw at any time. Participants were considered 101 
able to engage in physical activity comprising of a brisk walk, by satisfactorily completing a physical 102 
activity readiness questionnaire (PAR-Q), as well as an additional questionnaire on family history, 103 
medical history, present symptoms, and current pattern of physical activity [14,15]. Patients with T2DM 104 
were excluded as this condition may influence fat metabolism. In addition, recruited participants were 105 
not taking other medications which could knowingly interfere with fat metabolism. 106 
 107 
Experimental design  108 
Each participant made a total of three visits to the laboratory. All participants ceased lipid-lowering 109 
medication for a minimum of three weeks prior to Visit 1.The purpose of Visit 1 was to (a) prescreen the 110 
participant, (b) perform a submaximal exercise test on a treadmill to predict the participant’s maximum 111 
oxygen uptake (V̇O2max), and (c) calculate the individual treadmill settings (speed and gradient) which 112 
would enable the participant to walk at a power output of 50% V̇O2max in Visits 2 and 3. The latter were 113 
identical to each other with the notable exception that Visit 2 continued in the absence of the drug and 114 
Visit 3 in the presence of the drug. Visit 3 occurred after the participant had resumed their lipid-lowering 115 
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medication for a minimum of 3 weeks. Statin administration was verified verbally and by assessment of 116 
plasma lipids measured at the end of the drug versus no drug phases, on the mornings of Visits 2 and 3.  117 
 118 
Visit 1: Prescreening and submaximal exercise test  119 
Resting heart rate (HR), blood pressure, anthropometric assessment (height, weight, body mass index 120 
(BMI), waist and hip circumference), and percent body fat by bioelectrical impedance (Tanita BWB-800, 121 
Tanita Corporation, Japan) and by skinfolds analysis (biceps, tripceps, subscapular, suprailiac and 122 
abdominal) was measured [16]. 123 
Participants performed a submaximal exercise test on a treadmill to predict V̇O2max and to 124 
calculate the individual treadmill setting for each participant to exercise at 50% of their maximal 125 
capability in Visits 2 and 3. Ventilation (VE, l.min
-1
), oxygen uptake (V̇O2, l.min
-1), expired carbon 126 
dioxide (V̇CO2, l.min
-1) and respiratory exchange ratio (RER) (V̇CO2/V̇O2) were measured using a 127 
metabolic cart (ParvoMedics TrueMax 2400). HR was monitored via an electrocardiogram (ECG) and a 128 
HR monitor. Participants chose a comfortable walking speed at 0% gradient. With the speed constant, 129 
exercise intensity was increased a further two times, by increasing the gradient of the treadmill belt 130 
every 3-5 min after a stable exercise HR was recorded. The predicted maximum oxygen consumption 131 
was calculated by plotting exercise HR against oxygen consumption, with a line of best fit extrapolated 132 
to the point of each participant’s maximal predicted HR [15]. The relative perceived exertion (RPE) [15] 133 
and finger prick blood lactate, confirmed participants exercised at a submaximal level.  134 
 135 
Visits 2 and 3: Exercise at 50% V̇O2max in the absence and presence of a statin 136 
The exercise trials occurred at Visit 2 (-statin) and Visit 3 (+statin).Visit 3 occurred after participants 137 
had resumed medication for a minimum of three weeks. The two visits were otherwise identical. 138 
Participants arrived at the laboratory after an overnight fast (water permitted). A forearm vein was 139 
cannulated using a 20 gauge indwelling line (BD Insyte Autoguard, Becton Dickinson, UK). As the act 140 
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of venepuncture can increase some hormone levels by more than 50% [17], a stabilization period of 30 141 
min was allowed after the cannula was inserted into the forearm vein, and before collection of a fasting 142 
blood sample (6ml) into vacutainer tubes (Becton Dickinson, UK) containing ethylenediaminetetra-143 
acetic acid (EDTA). Fasting blood lipids, lactate and glucose were measured immediately. Participants 144 
then consumed a low fat 1MJ CHO meal, consisting of Special K cereal and low fat dairy or lactose free 145 
milk, followed by rest in a semi-inclined position. Participants commenced exercise 90 min after their 146 
meal. They walked on the treadmill at an intensity of 50% of their calculated V̇O2max (determined in 147 
Visit 1), corresponding to a ‘brisk walk’ for 45 minutes. The treadmill speed for each participant was 148 
that of Visit 1, and the treadmill gradient was determined using the formula: V̇O2=(0.1 x S)+(1.8 x S x 149 
G)+3.5; where V̇O2 is gross oxygen consumption mL.kg
-1
.min
-1 
at 50% of estimated V̇O2max, speed (S) 150 
is in metres.min
-1
 and G is percent grade expressed as a fraction [15]. The predetermined treadmill 151 
settings (speed and gradient) for each individual participant remained constant throughout the exercise 152 
session. VE, V̇O2, V̇CO2, and RER were measured to determine the proportion of CHO and fat 153 
metabolism during exercise. Calculation of carbohydrate and fat oxidation was by the classical 154 
stoichiometric equations of indirect calorimetry [18]; with carbohydrate oxidation (mg/min) 155 
=4.58V̇CO2–3.2V̇O2; and fat oxidation (mg/min) =1.7V̇O2–1.7V̇CO2. HR and RPE were monitored. 156 
Additional blood (each 6ml) was collected into EDTA-containing tubes immediately before exercise, 157 
and at time 15, 30 and 45 minutes of exercise, for the immediate measurement of glucose and lactate. 158 
Remaining blood samples were centrifuged (4ºC, 1560g, 10min, Heraeus Megafuge 1.0R, Hanau, 159 
Germany) and plasma was stored at -86ºC prior to the analysis of glycerol and FFA. 160 
 161 
Biochemistry 162 
Lipids (total cholesterol (TC), triglycerides (TG), low density lipoprotein-cholesterol (LDL-C) and high 163 
density lipoprotein-cholesterol (HDL-C)) (Cholestech LDX, CA, USA), glucose (HemoCue Glucose 164 
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201, Sweden), and lactate (Lactate Pro, ARKRAY, Inc., Japan) were measured in whole blood by 165 
reflectance photometry. Glycerol was measured in plasma using two colorimetric assays for comparison 166 
(Sigma, USA; and Cayman Chemical, USA) and the concentration determined at 550nm using an Expert 167 
Plus Microplate reader (Asys Hitech, Austria) and a Versa Max Microplate reader (Molecular Devices, 168 
USA). FFA were measured in plasma by colorimetric assay (Cell Biolabs, USA) at 570nm using the 169 
Versa Max Microplate reader. 170 
 171 
Food diary 172 
Participants completed a 3-day food diary, to calculate total caloric intake, and percentages of 173 
macronutrient and micronutrient intake during two non-consecutive weekdays and one weekend day. 174 
Data were entered into a nutritional database (Serve Nutrition Systems, Australia).  175 
 176 
Statistical Analysis 177 
Power calculations [19], based on a previous study [5] where participants walked at 50% V̇O2max in the 178 
presence or absence of a lipid-lowering agent, acipimox, determined that 11 participants would be 179 
sufficient to detect a significant decrease in plasma glycerol, assuming a 0.05 significance level and 80% 180 
power. The current study recruited 16 participants. All data are expressed as mean±standard error of the 181 
mean (SEM). The Student’s paired t-test compared fasting blood lipids±statin. A two-way repeated 182 
measures ANOVA examined differences between the two within-subject factors (treatment and time) for 183 
the physiological variables (HR, RPE, fat and CHO oxidation, % energy derived from fat and CHO, 184 
RER, V̇O2, glucose, lactate, glycerol, and FFA), measured during exercise. Where a significant two-way 185 
interaction was found (FFA), simple main effects examining differences between trials at each level of 186 
time and treatment were determined using the General Linear Model (GLM) Repeated Measures 187 
procedure. For cases without a significant two-way interaction, the main effect for treatment and time 188 
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were determined. Variables which did not meet Mauchly’s test of sphericity were interpreted using a 189 
Greenhouse-Geisser correction. For all data comparisons, unless indicated, significance is at P≤0.05. In 190 
using the GLM Repeated measures procedure for the FFA data, a Bonferroni adjustment was applied for 191 
the testing of multiple main effects, with a significance of p≤.05/3=p≤.016. Analysis was conducted 192 
using SPSS (SPSS Inc.,USA). 193 
 194 
  195 
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Results 196 
Patient characteristics 197 
The study engaged 13 males and 3 females, aged 39-82 years, taking a statin for hypercholesterolemia. 198 
In addition to hyperlipidemia, some patients had cardiovascular conditions (hypertension, coronary 199 
artery disease, heart murmur, aortic valve replacement, mild myocardial regurgitation, varicose veins), 200 
and arthritis. Two participants, with the permission of their medical practitioner, ceased taking 201 
metoprolol for the entire duration of the study as it interferes with fat metabolism [8].  202 
Patients were non-smokers or previous smokers who had ceased smoking 15-35 years earlier. 203 
Body composition data revealed that participants were on average overweight, had an increased disease 204 
risk relative to weight and waist circumference, and a moderate disease risk based on waist-hip ratio [15].  205 
Regarding physical activity, participants reported an average occupational activity intensity of 206 
1.5±0.2 (1=sedentary; 5=heavy labour), sport and leisure physical activity intensity of 6±0.4 (1=very 207 
light, 10=intense breathless), and exercise duration of 8±1 hours per week. Activities included cycling, 208 
swimming, board paddling, running, walking, dance, stair climbing, gym (circuit, weight training, 209 
aerobic classes), tennis, rollerblading, and martial arts. Aerobic fitness, indicated by a predicted V̇O2max, 210 
was categorized as ‘average’ for males (35±3 ml.kg-1.min-1) and ‘fair’ for females (23±0.5 ml.kg-1.min-1) 211 
[15]. The average percent daily consumption of protein and CHO was slightly higher, and lower, than 212 
the recommended 10-15% and 50-60%, respectively. The average percent daily consumption of <30% 213 
total fat was as recommended [20]. (Table 2) 214 
 215 
 216 
Lipid-lowering agents and blood lipoproteins 217 
Of the 16 patients, 11 were taking atorvastatin, with a daily dose range of 10-80mg (1=10mg, 6=20mg, 218 
3=40mg, 1=80mg). Rosuvastatin, at 10 mg/day was prescribed for 1 patient, and the remaining 4 219 
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patients were administering simvastatin at a dose range of 10-40mg/day (1=10mg, 1= 20mg, 2=40mg). 220 
Patients had been taking their drug for 3.5±0.6 years (range 0-10 years). There was one newly diagnosed 221 
individual who had not yet commenced his statin medication. All patients ceased taking their statin for 222 
3.4±0.2 weeks prior to their blood lipids analysis in Visit 2. Following this visit, patients recommenced 223 
taking their medication for 26±0.7 days. A significant decrease was observed in TC, LDL-C and 224 
TC/HDL-C when taking a statin, compared with in the absence of the drug (Table 3). Though not 225 
significant, a decrease in TG was also observed (p=.073).  226 
 227 
Energy expenditure and metabolism during exercise 228 
All participants completed the exercise tests. Exercise performed at 50% of V̇O2max for 45 minutes 229 
required a total energy expenditure of 268±20 kcal or 282±21 kcal in the absence or presence of a statin, 230 
respectively.  231 
No two-way interaction (between treatment and time) was found for fat or CHO oxidation, % 232 
energy derived from fat or CHO, RER, V̇O2, glycerol, glucose, lactate, HR, and RPE (Table 4). There 233 
was a two-way interaction between treatment and time for FFA (F(1.171, 12.879)=5.366, p=.033, 234 
epsilon=.58) at 45 minutes (p=.024). However, this effect was disregarded following correction for the 235 
testing of multiple main effects, with a Bonferroni adjustment, (p<.016), resulting in non-significance.  236 
As there was no 2x3 interaction, the main effect for treatment (irrespective of time point) and the 237 
main effect for time (irrespective of treatment) were examined. Regarding treatment, a difference 238 
between the conditions (±statin) was found for HR and V̇O2 (p≤0.05), with these variables lower in the 239 
presence of the statin. The main effect of time was significant for all variables (p≤0.05). 240 
 241 
Discussion 242 
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The current study has shown no evidence of an adverse effect of statins in dyslipidemic patients on the 243 
ability to use fat as a metabolic fuel during a moderate-intensity 45-minute walk. The results in this 244 
patient group are in agreement with previous research in healthy volunteers [5], where simvastatin 245 
treatment had no impact on fat oxidation or circulating plasma free fatty acids, glycerol and glucose 246 
during walking. This result is encouraging for patients, given that the importance of regular physical 247 
activity is recognized as a positive contributor to improving and maintaining health [4]. Indeed, this 248 
study supports positive messaging to patients taking statins; that they may engage in regular exercise. 249 
This does to some extent counteract the recently suggested association of statins with an increased risk 250 
of T2DM [21]. Furthermore, implementation of a healthy diet and regular aerobic exercise, while on 251 
statin medication, may for some patients, enhance the possibility of a medically managed reduction in 252 
their statin dose or even complete cessation of this medication. The current study provides reassurance 253 
for both patients and their advising physicians, that it is possible to engage effectively in moderate-254 
intensity exercise without the prescribed statin compromising the ability to use fat stores as a fuel to 255 
carry out the exercise session.  256 
The lack of an adverse effect on fatty acid mobilization by statins may be due to the fact that 257 
their action is thought to be largely confined to the liver [22], rather than adipose tissue. Preliminary 258 
research by our group on ezetimibe (Ezetrol), a non-statin whose action is confined to inhibiting 259 
cholesterol absorption from the intestine [23], has also shown no effect of this drug on fat metabolism 260 
during 45 minutes of moderate-intensity walking (data not published). In contrast, acipimox and fibrates, 261 
significantly inhibit HSL in adipose tissue, which results in inhibiting the release of FFA during exercise 262 
from this site [5,6]. Fibrates may also reduce availability of FFA to skeletal muscle, by increasing the 263 
uptake of FFA into liver with the induction of a fatty acid transporter protein [24]. 264 
The findings from this study, therefore make a valuable contribution to the somewhat confusing 265 
information on statins and metabolism. It has been suggested that statins, by lowering cholesterol, may 266 
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affect mouse membrane calveolae, important in fatty acid transport [25]. Statins have been implicated in 267 
impairing mitochondrial function, evidenced by increased lactate production, elevated intramuscular 268 
lipid stores, decreased mitochondrial activity (measured by a decrease in cytochrome C activity) and 269 
lower CoQ10 levels [26,27]. However, despite the above, it has been found that a decrease in circulating 270 
CoQ10 does not result in a reduction in muscle CoQ10 [28]. Furthermore, reviews to date, have not 271 
concluded that CoQ10 is required when taking statins [29,30].  272 
Other conflicting results include reports in humans of increased resting RER with statins,   273 
indicating a possible shift from fat to CHO metabolism [10,31]. A 12-week aerobic training study 274 
measured a greater increase in V̇O2max in a -statin, compared with +statin group. The authors reported a 275 
decline in muscle citrate enzyme activity, suggesting that statins may affect mitochondria [32]. However, 276 
in contrast to the above, there are reports of simvastatin therapy in patients having no effect on RER or 277 
aerobic fitness (V̇O2max) suggesting no effect on fat metabolism and aerobic capacity [30]. Additionally, 278 
a 30% increase in V̇O2max, indicating an increase in aerobic fitness, has been reported in patients on 279 
rosuvastatin undergoing exercise training for 10 weeks [13].  280 
The conflicting results in the literature, are due to many variables, including that of studying 281 
different patient groups in either the presence or absence of the drug. The current study eliminated this 282 
variable, adopting a longitudinal design, with all participants required to undertake exercise with and 283 
without a statin. Based on previous research in healthy volunteers [5], the current study adopted a 3-284 
week treatment period verified by assessment of plasma lipids at the end of the drug versus no drug 285 
phases. The treatment period significantly lowered TC and LDL-C, confirming that it was of sufficient 286 
length to obtain the desired effect of lowering circulating lipids, enabling patients to serve as suitable 287 
controls.  288 
To minimize disruption to patients, the current study did not adopt a cross-over design, with all 289 
patients experiencing the prescreening session and the first 45-minute walk in the absence of the drug, 290 
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and the second 45-minute walk in the presence of the drug. Additionally, researchers did not interfere 291 
with each individual patient’s statin type and therapeutic dosage, to keep with their real-life situation, 292 
controlled by their physician. This, along with the age range of the patients, was not considered a 293 
limitation, as the strength of this study is in having each patient serve as their own effective control.  294 
This study also concentrated on the effect of statins without the confounding variable of 295 
decreased blood glucose during exercise. The mean energy expenditure during exercise was 1.1MJ (282 296 
kcal), well below the CHO energy reserve of 8-11MJ for a well-nourished adult [5,33]. Additionally, 297 
participants consumed a low fat 1MJ CHO meal 90 minutes prior to exercise. Blood glucose levels 298 
remained stable during both trials. The decreasing contribution of CHO and increasing contribution of 299 
fat as a fuel during the walk was similar in the ±statin exercise sessions. At 45 minutes of walking, fat 300 
oxidation peaked at an average of 0.28g/min. 301 
The chosen modality and intensity of exercise, with a duration of 45 minutes, was adopted as it 302 
has been reported as manageable for patients and ideal for maximizing cardiovascular health benefits, 303 
significantly reducing morbidity and mortality [5,34]. Though it appears that statins do not impact fat 304 
metabolism when exercising under these conditions, future studies examining different exercise 305 
modalities, intensities and duration, are recommended. 306 
There are many people world-wide on statins. Amongst this group are individuals who are 307 
considered capable of adopting a healthier lifestyle incorporating regular exercise. This study 308 
demonstrates that statins do not compromise fat metabolism during moderate-intensity aerobic exercise, 309 
and therefore do not contribute to premature fatigue and an inability of the patient to complete the 310 
exercise. More emphasis may therefore be placed on encouraging regular physical activity in patients to 311 
maximize the benefits of concomitant therapies such as pharmaceutical intervention. 312 
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Table 1. Patient characteristics. 455 
 456 
Variable  
  
N 16 
Gender 13M, 3F 
Age (years)  57±3 
RHR (mmHg)  70±3 
SBP (mmHg) 125±2 
DBP (mmHg)  80±2 
MAP (mmHg)  94±2 
Height (cm) 173±2 
Weight (kg)   84±3 
BMI (kg/m
2
)   28±1 
Waist (cm)   95±3 
Hip (cm) 103±2 
Waist-hip ratio    0.91±0.02 
%BF (skinfolds)  33±2 
%BF (Tanita)  27±2 
V̇O2max (ml.kg
-1
.min
-1
)  33±3 
  
 457 
N:number of participants; M:male; F:female; RHR:resting heart rate; SBP:systolic blood pressure; 458 
DBP:diastolic blood pressure; MAP:mean arterial pressure; BMI:body mass index; %BF:percent body 459 
fat; V̇O2max:maximal oxygen uptake. Values are mean±SEM. 460 
 461 
 462 
 463 
 464 
 465 
 466 
 467 
 468 
 469 
 470 
 471 
 472 
 473 
 474 
 475 
 476 
 477 
 478 
 479 
 480 
 481 
 482 
 483 
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Table 2. Dietary intake. 484 
 485 
 Energy or  
% Macronutrient intake 
  
Total energy (kJ/day) 10,111±927 
Carbohydrate (%)   48±2 
Protein (%)   17±1 
Fat (%)   28±2 
Monounsaturated fat (%)      11±0.8 
Polyunsaturated fat (%)       5±0.5 
Saturated fat (%)       9±0.5 
Alcohol (%)    7±2 
  
 486 
Values are mean±SEM. 487 
 488 
 489 
 490 
 491 
 492 
 493 
 494 
 495 
 496 
 497 
 498 
 499 
 500 
 501 
 502 
 503 
 504 
 505 
 506 
 507 
 508 
 509 
 510 
 511 
 512 
 513 
 514 
 515 
 516 
 517 
 518 
 519 
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Table 3. Fasting blood lipids (mmol/L) in the absence(-) and presence(+) of a statin. 520 
 521 
 -statin +statin p-value 
    
Total cholesterol 5.76±0.31 4.11±0.14 .000 
Triglyceride 1.69±0.41 1.14±0.15 .073  
HDL-C 1.31±0.10 1.28±0.10 .908 
LDL-C 3.77±0.21 2.32±0.10 .000 
TC/HDL 4.54±0.40 3.39±0.20 .001 
    
 522 
HDL-C:high density lipoprotein cholesterol; LDL-C:low density lipoprotein cholesterol; TC/HDL:total 523 
cholesterol/high density lipoprotein ratio. Values are mean±SEM. p≤0.05 significantly different between 524 
±statin (Student’s paired t-test). 525 
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Table 4. Physiological variable measured in participants during a walk at time = 15, 30 and 45 526 
minutes in either the absence(-) or presence(+) of a statin. 527 
 528 
  -statin   +statin   
Variable 15 min 30 min 45 min 15 min 30 min 45 min p-value 
        
Fat oxidation 
(g/min) 
0.16±0.02 0.23±0.01 0.29±0.02 0.13±0.02 0.19±0.02 0.27±0.02 .622 
CHO oxidation 
(g/min) 
  1.8±0.15   1.5±0.13   1.3±0.13   1.7±0.15   1.5±0.13   1.3±0.11 .312 
%Fat    19±2    31±2    38±2    19±3    28±2    38±2 .567 
%CHO    82±2    70±2    63±2    82±3    74±3    63±2 .390 
RER   .93±.007   .90±.005   .88±.006   .93±.009   .91±.009   .88±.007 .393 
Glycerol (µmol/l) 
(Cayman) 
 175±24  202±20  232±22  159±15  167±15  180±13 .080 
Glycerol (µmol/l) 
(Sigma) 
 102±8  125±11  150±15    99±15  105±14  125±13 .178 
FFA (µmol/L)    47±8   82±12  138±22    53±13    70±16  104±20 .033 
V̇O2 (ml.kg
-1
.min
-1
)    16±1.2   15±1.3    15±1.3    15±1.2    15±1.3    15±1.3 .452 
Glucose (mmol/l)   4.2±0.2  4.0±0.2   4.2±0.1   4.3±0.3   4.2±0.2   4.3±0.1 .883 
Lactate (mmol/l)   1.3±.09  1.0±.06   1.0±.09   1.2±.08   1.0±.06   0.9±.03 .426 
HR (bpm)  109±3 110±3  111±3  101±3  103±3  104±3 .756 
RPE    11±0.4   11±0.4    12±0.4    11±0.4    11±0.4    11±0.4 .596 
        
 529 
CHO:carbohydrate; %Fat:percentage kcal derived from fat; %CHO:percentage kcal derived from 530 
carbohydrate; RER:respiratory exchange ratio; FFA:free fatty acid; V̇O2:oxygen uptake; HR(bpm):heart 531 
rate (beats per minute); RPE:rating of perceived exertion. Data are mean±SEM. Significance is P≤ 0.05, 532 
repeated measures analysis of variance (ANOVA). No significance achieved for ‘treatment and time’ for 533 
any variables (exception FFA). For FFA, significance is p≤0.016 (Bonferroni adjustment) with the 534 
simple main effect also not statistically significant. 535 
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